Vardhman Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 24-10-2024
- Paid Up Capital ₹ 1.20 M
as on 24-10-2024
- Company Age 28 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.10 Cr
as on 24-10-2024
- Satisfied Charges ₹ 6.51 Cr
as on 24-10-2024
- Revenue 0.24%
(FY 2023)
- Profit 6.42%
(FY 2023)
- Ebitda -45.19%
(FY 2023)
- Net Worth -16.37%
(FY 2023)
- Total Assets 2.92%
(FY 2023)
About Vardhman Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.20 M.
The company currently has active open charges totaling ₹10.10 Cr. The company has closed loans amounting to ₹6.51 Cr, as per Ministry of Corporate Affairs (MCA) records.
Manu Jain, Arun Jain, Abha Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U85110UP1996PTC020052
- Company No.
020052
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 May 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Meerut, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Vardhman Drugs?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manu Jain  | Director | 31-May-1996 | Current |
| Arun Jain | Director | 31-May-1996 | Current |
| Abha Jain | Director | 31-May-1996 | Current |
| Surabhi Jain | Director | 20-May-2007 | Current |
Financial Performance of Vardhman Drugs.
Vardhman Drugs Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.24% increase. The company also saw a slight improvement in profitability, with a 6.42% increase in profit. The company's net worth observed a substantial decline by a decrease of 16.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vardhman Drugs?
In 2023, Vardhman Drugs had a promoter holding of 94.58% and a public holding of 5.42%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 10 Nov 2021 | ₹6.00 Cr | Open |
Others Creation Date: 23 Feb 2018 | ₹4.10 Cr | Open |
Others Creation Date: 29 Aug 2018 | ₹8.00 M | Satisfied |
How Many Employees Work at Vardhman Drugs?
Vardhman Drugs has a workforce of 32 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vardhman Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vardhman Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
